Annuska Glas Email & Phone Number

Netherlands

Amsterdam Area, Netherlands

• Innovator and Developer of ImPrint and RePrint
• Spearheaded Digital Pathology program using AI based image analysis
• Digital MammaPrint/BluePrint development
• FDA 510(k) clearance for MammaPrint NGS – decentralized

• Management Team member
• Participation in provision of strategic direction, tactical oversight and technical expertise for all company activities
• One of the first employees building the company
• Innovator and developer of all commercial and research products at Agendia (e.g. MammaPrint and BluePrint) in all its variations in technology platforms and regulatory requirements (FDA, EU-IVDR and others)
• Spearheading AI based research (digital products)
• 6 issued patents and 12 additional patents submitted in different cancer fields

Amsterdam Area, Netherlands; California, USA

• Strategic direction and management of the Research and Development (R&D) program, from new product proposal to commercialization
• Established stage gate review process and improved design control processes according to Food and Drug Administration (FDA), Good Manufacturing Practices (GMP) requirements and conform European regulations (CE-IVD)
• Product-, process-improvements and quality monitoring of diagnostic results

Amsterdam (Netherlands) And Irvine, CA

• Leading product support departments in Irvine CA and Amsterdam
• Transferred gene expression based tests(MammaPrint and BluePrint) from fresh tissue to a test based on FFPE tissue
• Responsible for technical development of products (Accuracy, precision, clinical accuracy, software development)
• New product transfer (ColoPrint, BluePrint) to operations (Netherlands and USA)

• Development of BluePrint and ColoPrint
• Validation laboratory processes and products in an additional lab (Irvine CA, USA).
• Maintain and improve Quality and regulatory (FDA) documentation system for R&D
• Raw material qualifications and equipment validations
• CLIA accreditation

• Translating the 70-genes Amsterdam signature from research to Diagnostic test (MammaPrint)
• Managing high throughput microarray data and developing analysis pipelines for research and diagnostics data
• Development of quality control system for diagnostic tests
• Development TargetPrint (ER,PR Her2 single gene read out)
• Development of CupPrint (Cancer of unknown primary)

Amsterdam

• The Netherlands Cancer Institute, www.nki.nl, Amsterdam, The NetherlandsProject: Molecular classifiers in follicular lymphoma and breast cancer.Among the responsibilities were:
• Designing and performing microarray experiments on samples from (follicular) lymphoma and breast cancer patients,
• Data analysis and interpretation of the results.
• Optimization of microarray protocols
• Development bioinformatics data analysis tools (database and analysis tools in R and Matlab).
• Training colleagues and students in Microarray experiments and data analysis.

Seattle

• Studied the nature of B-cell defects leading to the humoral deficiency in bone marrow transplant (BMT) recipients. The processes involved in generating and selecting the antibody repertoire are largely functional.
• Validation of Applied Biosystems Model 373A DNA sequencing system at the institute
• Sequence analysis and interpretation of VH family specific germline and rearrangement libraries (VH3 and VH4),
• Construction of cDNA libraries and germline libraries from subsets of peripheral blood B cells sorted using flow cytometry and beads.
• Optimization of motif specific hybridizations to identification of individual human VH genes and detection of somatic mutations using 96 well format dot blot nylon membranes
• Isolation of B- and T-cell populations from peripheral and cord blood

Phd, Molecular Genetics

Molecular Biology

Immunology

Msc, Molecular Biology

Activities and Societies: Chairman of Vereniging Dijkgraaf (>600 members)